Dividend Stocks Overview - Stocks have outperformed other asset classes over the past century, with equities beating gold by 5.6% annually, housing prices by 6.6%, Treasuries by 6.8%, and oil by 8.4% annually [1] - Dividend stocks have historically outperformed non-dividend payers with less risk, making them a strong choice for long-term investment [1] - Between 1973 and 2022, dividend-growing stocks returned over 10%, while stocks that cut dividends lost money [1] LVMH Moet Hennessy Louis Vuitton (LVMUY) - LVMH owns 75 luxury brands across various categories, including Louis Vuitton, Dior, Fendi, and Sephora [2] - The company enjoys gross margins of almost 70% and operating margins above 25% [2] - LVMH's customer base represents the top 5% of luxury spenders, accounting for 40% of global luxury sales [3] - The company pays dividends twice a year, with a 16% annual growth rate over the past five years and 13% over the last decade [3] - Free cash flow (FCF) has grown exponentially, supporting its dividend payouts [3] Johnson & Johnson (JNJ) - Johnson & Johnson focuses on high-margin pharmaceutical drugs, which make up 65% of its total revenue [5] - The company has a portfolio of billion-dollar therapies, including Stelara, Tremyfa, Darzalex, and Simponi [5] - Revenue is forecast to grow 7-8% annually, with adjusted profits growth of 12-13% [5] - Johnson & Johnson spun off its consumer products business into Kenvue, allowing it to focus more on healthcare [5] - The company has paid dividends every year since 1944 and has raised its payout for 61 consecutive years [6] - It currently yields a 2.8% annual dividend with a payout ratio of 35%, indicating room for future growth [6] Lowe's (LOW) - Lowe's has delivered a 511% total return since 2014, outperforming the S&P 500's 210% return [7] - The company has increased its dividend at a compounded annual rate of 20% over the last decade and has raised it for 60 consecutive years [7] - Lowe's has a low payout ratio of 34%, supported by strong free cash flow of $11 per share compared to an annual dividend of $4.38 per share [7][8] - The company is the largest retailer of appliances with a 28% market share, ahead of Home Depot (23%) and Best Buy (14%) [8] - Lowe's business is resilient during housing market declines, as homeowners continue to invest in home improvement projects [8]

Sundry Photography Johnson & Johnson (NYSE:JNJ) reported Q4 earnings on January 23 that exceeded expectations, reaffirming guidance for FY24. The company recently spun off its consumer health subsidiary, Kenvue (KVUE), in 2023, redirecting its focus toward pharmaceuticals and medical devices. I am initiating coverage with a 'Buy' rating and a fair value target of $180 per share. 5-7% Growth in their Pharma Business JNJ stands as the second-largest pharmaceutical company globally, presenting a diverse po ...

OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its role in the opioid addiction crisis.“They knew what the harm was. They did it anyway,” Attorney General Bob Ferguson told reporters Wednesday.The attorney general’s announcement came as opioid overdose deaths more than doubled from 2019 to 2022, with 2,048 deaths recorded in 2022, according to the most recent ...

Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding quarter in 2022. The pharmaceutical giant disclosed a net income of $4.13 billion, a rise from the $3.23 billion reported in the previous year. During their most recent quarterly earnings call on Tuesday (Jan. 23), J&J executives said the earnings growth in the first half of the year would be positively influence ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California.Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go t ...

Johnson & Johnson Innovative Medicine Pipeline Key Events in 2024* POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA SSSuuummm ooofff PRCrehogegicorkan mC Ch hCaahnnaggneege SSSuuummm ooofff PRCrehogegicorkan mC Ch hCaahnnaggneege SSSuuuPmmmh oaoosfff e PRC rIehIogIegicorkan mC Ch hCaahnnaggneege OPSUMIT (macitentan) US OPSUMIT (macitentan) US SIMPONI (golimumab) TREMFYA (guselkumab) EU Pediatric Pulmonary Arterial Hypertension Pediatric Pulmonary Arterial Hypertension EU Pediatric ...

Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Conference Call January 23, 2024 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman & CEO Joseph Wolk - EVP & CFO Conference Call Participants Joanne Wuensch - Citibank Terence Flynn - Morgan Stanley Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Louise Chen - Cantor Fitzgerald Matt Miksic - Barclays Geoff Meacham - Bank of America Danielle Antalffy - UB ...

Shares of Johnson & Johnson (JNJ -1.59%) were sliding today as the diversified healthcare company edged past estimates in its fourth-quarter earnings report, but agreed to pay $700 million to settle lawsuits saying that its talc-based baby powder caused cancer. J&J also announced a settlement with the state of Washington over opioid-related claims for $149.5 million and said it had now resolved all pending litigation over the opioid crisis. As of 11:08 a.m. ET, the stock was down 2%. A good, but not good en ...

Johnson & Johnson’s (JNJ) fourth-quarter 2023 earnings came in at $2.29 per share, which beat the Zacks Consensus Estimate of $2.27. Earnings rose 11.7% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported fourth-quarter earnings of $1.70 per share, up 39.3% from the year-ago quarter.Sales of this drug and medical devices giant came in at $21.4 billion, beating the Zacks Consensus Estimate of $21.1 billion by a slight ma ...